Fixed drug eruption related to sunitinib: a case report
General Material Designation
[Article]
First Statement of Responsibility
Bhatia, Anuradha; Jha, Niharika; Kanish, Bimal
SUMMARY OR ABSTRACT
Text of Note
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor. It has been approved for the treatment of gastro-intestinal stromal tumor and advanced renal cell carcinoma. Fixed drug eruption related to sunitinib is a rare cutaneous adverse drug reaction.